Ista petitions FDA over eye drug label

03/6/2011 | Reuters

Ista Pharmaceuticals sent a petition asking the FDA to reject any generic version's application for the withdrawn twice-daily eye medicine Xibrom that uses the original labeling. Ista said any generic's label should include a reference to the option of the once-daily dose.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX